Zacks Investment Research downgraded shares of Halyard Health Inc. (NYSE:HYH) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “

A number of other brokerages also recently weighed in on HYH. Deutsche Bank AG lifted their price target on Halyard Health from $36.00 to $41.00 and gave the company a buy rating in a report on Wednesday, August 10th. TheStreet upgraded Halyard Health from a sell rating to a hold rating in a report on Friday, July 8th. Finally, Stifel Nicolaus lifted their price target on Halyard Health from $37.00 to $38.00 and gave the company a buy rating in a report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $34.20.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Halyard Health (NYSE:HYH) opened at 33.99 on Tuesday. The stock’s 50 day moving average is $35.11 and its 200-day moving average is $32.79. Halyard Health has a 52-week low of $22.76 and a 52-week high of $37.31. The company’s market capitalization is $1.59 billion.

Halyard Health (NYSE:HYH) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.09. Halyard Health had a positive return on equity of 8.91% and a negative net margin of 27.63%. The business had revenue of $400 million for the quarter, compared to the consensus estimate of $383.08 million. During the same quarter in the previous year, the company posted $0.52 earnings per share. Halyard Health’s revenue for the quarter was up 2.7% compared to the same quarter last year. Analysts predict that Halyard Health will post $1.82 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its position in shares of Halyard Health by 204.2% in the second quarter. Nisa Investment Advisors LLC now owns 14,897 shares of the company’s stock worth $484,000 after buying an additional 10,000 shares during the period. Gateway Investment Advisers LLC purchased a new position in shares of Halyard Health during the second quarter worth approximately $439,000. BNP Paribas Arbitrage SA increased its position in shares of Halyard Health by 799.0% in the second quarter. BNP Paribas Arbitrage SA now owns 28,740 shares of the company’s stock worth $935,000 after buying an additional 25,543 shares during the period. Springbok Capital Management LLC increased its position in shares of Halyard Health by 151.9% in the first quarter. Springbok Capital Management LLC now owns 6,800 shares of the company’s stock worth $195,000 after buying an additional 4,100 shares during the period. Finally, Nuveen Asset Management LLC increased its position in shares of Halyard Health by 22.2% in the first quarter. Nuveen Asset Management LLC now owns 85,044 shares of the company’s stock worth $2,443,000 after buying an additional 15,467 shares during the period. Hedge funds and other institutional investors own 82.93% of the company’s stock.

Halyard Health Company Profile

Halyard Health, Inc seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company operates through two segments: Surgical and Infection Prevention (S&IP) and Medical Devices. Its S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections.

5 Day Chart for NYSE:HYH

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.